~~<i id='1AC8C80892'><strike id='1AC8C80892'><tt id='1AC8C80892'><pre id='1AC8C80892'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-10-04 08:50:18 Page View：2184

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden administration plans revamp of organ transplant system
Next article： In Memoriam: Notable people who died in 2023

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Can medical device makers keep up in the race to treat obesity?

KatyLemayforSTATThemakersofminimallyinvasivesurgicaldevicesseemedpoisedtocaptureawideswathoftheobesi

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Chimpanzees, like humans and whales, get menopause: Study

GUERCHOMNDEBO/AFPviaGettyImagesChimpanzees—they’rejustlikeus.Femalechimps,itturnsout,gothroughmenopa